311 related articles for article (PubMed ID: 31228203)
1. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
2. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
[TBL] [Abstract][Full Text] [Related]
4. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
5. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
[TBL] [Abstract][Full Text] [Related]
7. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
Loree JM; Mulder KE; Ghosh S; Spratlin JL
Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
[TBL] [Abstract][Full Text] [Related]
8. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
[TBL] [Abstract][Full Text] [Related]
9. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
12. A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy.
Yoshimatsu K; Ishibashi K; Koda K; Yokomizo H; Oda N; Oshiro M; Kato H; Oya M; Nakajima H; Ooki S; Maekawa H; Matsunami T; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Yokoyama M; Ishida H
Surg Today; 2019 Jun; 49(6):498-506. PubMed ID: 30953164
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
14. Real-world tolerance and outcomes of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer-Does dose intensity matter?
Yoon R; Wilkinson K; Gabriel G; Kadaan N; Roberts T; Lim S; Asghari R; Lee CS; Chua W; Ng W
Asia Pac J Clin Oncol; 2024 Feb; 20(1):63-70. PubMed ID: 37211922
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
17. Optimal duration of adjuvant therapy for stage III colon cancer.
Kadakia KC; Worrilow WM; Coley H; Salem ME
Clin Adv Hematol Oncol; 2019 May; 17(5):289-298. PubMed ID: 31188808
[TBL] [Abstract][Full Text] [Related]
18. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
Osawa H; Handa N; Minakata K
Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
[TBL] [Abstract][Full Text] [Related]
20. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
